MedPath

Study of Effect of Purgation therapy( virechan) on Serum IgE antibody Level In Atopic Dermatitis(Eczema)

Phase 3
Conditions
Health Condition 1: L209- Atopic dermatitis, unspecified
Registration Number
CTRI/2024/06/069620
Lead Sponsor
Ayurvedic and Unani Tibbia college and hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Patient with known case of atopic dermatitis along with specific symptomatology of

atopic dermatitis according to criteria of American academy dermatology of eczema

with increased IgE level .

2.Patient of Age group 18-60 years of either sex.

Exclusion Criteria

1.Patients who are contraindicated for virechana karma- like lower GI bleeding, Prolapse of rectum, incontinence of stool etc. will not be included in the trial group

2. Patients of other skin disorders (like psoriasis,seborrheic dermatitis ,scabies,contact dermatitis,lupus erythematous etc.) .

3. Patients with comorbid condition such as Diabetes mellitus(having HbA1c greater than 7.5 percent with or without antihyperglycemic medication).

4. Patients with renal or hepatic impairment (Sr. creatinine greater than 1.8 mg/dl, SGOT and SGPT greater than Five times of upper limit .

5. Patients who are taking immunomodulatory drug since last 2 month, antitubercular ,anti-retroviral drugs,steroids,antibiotics, etc .

6. Patients requiring emergency treatment

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath